{"gene":"APLN","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2005,"finding":"Apelin peptides are derived from a single gene and activate the 7-transmembrane G-protein-coupled receptor APJ; apelin peptides also represent substrates for ACE2 carboxypeptidase, which cleaves and inactivates them.","method":"Biochemical/pharmacological characterization; review of experimental literature","journal":"Pharmacology & therapeutics","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple labs, consistent with broad corpus","pmids":["15907343"],"is_preprint":false},{"year":2008,"finding":"Hypoxia induces apelin expression in endothelial and vascular smooth muscle cells via HIF-1α binding to a hypoxia-responsive element (HRE) located within the first intron (+813/+826) of the human apelin gene; siRNA knockdown of HIF-1α abolished hypoxia-induced apelin expression; apelin or APJ receptor knockdown inhibited hypoxia-induced endothelial cell proliferation in vitro and vessel regeneration in zebrafish.","method":"Transient transfection reporter assay, chromatin immunoprecipitation (ChIP), siRNA knockdown, in vivo zebrafish fin regeneration model","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP demonstrating HIF-1α binding to endogenous locus, reporter assays with mutagenesis, functional knockdown in vitro and in vivo","pmids":["18617693"],"is_preprint":false},{"year":2007,"finding":"Apelin-13 and apelin-36 produce cardioprotection against ischemia-reperfusion injury by activating the PI3K-Akt and p44/42 MAPK (RISK pathway) and delaying mitochondrial permeability transition pore (MPTP) opening; pharmacological inhibition of PI3K (LY294002) or MEK (UO126/MEK inhibitor 1) abolished the protective effects.","method":"In vivo open-chest rodent I/R model, in vitro Langendorff perfusion and isolated cardiomyocytes, Western blot for pathway activation, pharmacological inhibitors of PI3K and MEK","journal":"Basic research in cardiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal models (in vivo and in vitro), pathway inhibitor experiments, replicated across infarct size and MPTP assays","pmids":["17694254"],"is_preprint":false},{"year":2007,"finding":"Zebrafish apelin (ligand) and its receptor Agtrl1b (APJ homolog) control heart field formation during gastrulation by directing convergence of cardiac precursors from lateral plate mesoderm toward the midline; reduced or excess Apelin/Agtrl1b function caused deficiency of cardiac precursors and heart defects.","method":"Zebrafish loss-of-function and gain-of-function genetic experiments, in situ hybridization, confocal microscopy of cardiac precursor migration","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function and gain-of-function with defined cardiac morphogenetic phenotype in zebrafish ortholog","pmids":["17336905"],"is_preprint":false},{"year":2015,"finding":"Apelin-APJ signaling promotes brown adipocyte differentiation and browning of white adipocytes by increasing expression of brown adipogenic and thermogenic transcription factors via PI3K/Akt and AMPK signaling pathways; apelin also increases mitochondrial biogenesis, PGC1α and UCP1 expression, and oxygen consumption.","method":"In vitro adipocyte differentiation assays, PI3K/Akt and AMPK pathway pharmacological inhibitors, in vivo mouse model, gene expression and mitochondrial function assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo data with pathway inhibitors, single lab","pmids":["25931124"],"is_preprint":false},{"year":2015,"finding":"APLN is robustly expressed in sprouting (tip) endothelial cells during angiogenesis and is re-activated in adult endothelial cells after ischemia; genetic ablation using Apln-CreER specifically labels sprouting but not quiescent vasculature, and abolishment of VEGF-VEGFR2 signaling reduced APLN expression in sprouting endothelium.","method":"Apln-CreER genetic lineage tracing mouse model, tumor angiogenesis and ischemia models, genetic ablation of sprouting endothelial cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic lineage tracing with functional consequence, multiple pathological models","pmids":["25597280"],"is_preprint":false},{"year":2015,"finding":"Elabela (ELA)/Toddler activates the apelin receptor (APJ) in mammalian cells, causing receptor internalization, suppression of cAMP production (EC50 ~11 nM), ERK1/2 phosphorylation (EC50 ~14 nM), and weak intracellular calcium mobilization; ELA also induces angiogenesis in endothelial cells and relaxes mouse aortic blood vessels.","method":"Reconstituted HEK293 and CHO cell systems with GFP-APJ fusion, cAMP assay, ERK1/2 phosphorylation assay, calcium mobilization, aortic ring relaxation ex vivo","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — reconstituted receptor signaling with quantified EC50 values, multiple orthogonal assays, ex vivo functional validation","pmids":["25639753"],"is_preprint":false},{"year":2017,"finding":"Crystal structure of human apelin receptor (APJR) at 2.6 Å resolution in complex with a 17-amino acid apelin mimetic peptide revealed a lactam-constrained, curved two-site ligand binding mode; mutation analysis and molecular dynamics simulations with apelin-13 identified key binding residues for apelin recognition and specificity.","method":"X-ray crystallography (2.6 Å), site-directed mutagenesis, molecular dynamics simulation","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mutagenesis and MD validation","pmids":["28528775"],"is_preprint":false},{"year":2016,"finding":"Apelin-induced internalization of APJ occurs via clathrin-coated vesicles (CCVs) in a GRK2-mediated phosphorylation-dependent, β-arrestin1-independent, EPS15- and dynamin-dependent manner; [Pyr1]apelin-13 stimulation also causes rapid desensitization of APJ-mediated ERK1/2 (ppERK1/2) signaling through upstream APJ-specific adaptive changes rather than internalization.","method":"Dominant-negative mutant cDNA constructs (GRK2, β-arrestin1, EPS15, dynamin), semi-automated fluorescence imaging of HA-tagged APJ internalization in HEK293 cells, ERK1/2 phosphorylation assays","journal":"Molecular and cellular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — dominant-negative constructs for mechanistic dissection, multiple trafficking components tested, single lab","pmids":["27492965"],"is_preprint":false},{"year":2014,"finding":"Apelin-13 stimulation of APJ activates Gαi2 and Gαi3 through molecular rearrangement (rather than classical dissociation), while Gαo and Gαq are activated through classical dissociation; Gαi1 showed little change after apelin-13 stimulation.","method":"BRET and FRET in live HEK293 cells expressing APJ and fluorescent G-protein subunits","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell BRET/FRET measurements, single lab","pmids":["25193074"],"is_preprint":false},{"year":2006,"finding":"Apelin and APJ are expressed in human osteoblasts; apelin stimulates osteoblast proliferation via APJ-dependent activation of PI3K/Akt (but not JNK, p38, or ERK1/2); siRNA-mediated APJ knockdown and LY294002 (PI3K inhibitor) abolished apelin-induced proliferation.","method":"RT-PCR, Western blot, siRNA knockdown of APJ, pharmacological PI3K inhibitor (LY294002), cell proliferation assay","journal":"Regulatory peptides","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with pathway inhibitor, single lab, two orthogonal methods","pmids":["16563531"],"is_preprint":false},{"year":2018,"finding":"Apelin inhibition reduces tumor angiogenesis, remodels the tumor microenvironment by reducing polymorphonuclear myeloid-derived suppressor cell infiltration, and prevents resistance to anti-angiogenic RTK inhibitor therapy; apelin loss alone accelerated tumor cell invasion, but combined apelin/VEGFR2 blockade was synergistically effective.","method":"Genetic knockout and pharmacological inhibition of apelin/APLNR in mammary and lung cancer mouse models, tumor microenvironment analysis","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic and pharmacological models, multiple tumor types, single lab","pmids":["31267692"],"is_preprint":false},{"year":2019,"finding":"APLN is transcriptionally upregulated by active β-catenin, which binds to the APLN promoter to induce transcription in hepatocellular carcinoma; APLN activates PI3K/Akt via APLN receptor, leading to increased p-GSK3β and cyclin D1, promoting G1/S cell cycle progression and inhibiting apoptosis.","method":"β-catenin ChIP at APLN promoter, ectopic expression and siRNA knockdown, Western blot for PI3K/Akt pathway components, xenograft mouse model","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for upstream regulator, mechanistic pathway analysis with knockdown, in vivo xenograft, single lab","pmids":["31410213"],"is_preprint":false},{"year":2019,"finding":"APLN protects against abdominal aortic aneurysm by preventing smooth muscle cell apoptosis and oxidative stress; APLN induces ACE2 expression in the vasculature; neutral endopeptidase (NEP) is a major enzyme that metabolizes and inactivates APLN-17 in human AAA tissue; a NEP-resistant APLN-17 analog (APLN-NMeLeu9-A2) ameliorated Ang II-mediated AAA in mice.","method":"Apln knockout mice, Ang II-induced AAA model, cultured murine and human aortic SMCs, pharmacological and genetic approaches, peptide analog design and synthesis, high-fat diet Ldlr-/- mouse model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple genetic models, in vitro mechanistic work, identification of degrading enzyme, therapeutic analog validation in vivo","pmids":["31189595"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM structures of fully active human apelin receptor (APJR) complexed with heterotrimeric G protein in both 2:1 (dimer:G protein) and 1:1 (monomer:G protein) stoichiometric ratios were determined; structural differences in G protein engagement between dimeric and monomeric APJR suggest a role for stoichiometry in GPCR-G protein coupling and downstream signaling; a small hydrophobic dimer interface was identified.","method":"Cryo-EM single-particle analysis with ELA and synthetic small molecule ligands","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryo-EM structure with functional implications, two ligand conditions","pmids":["35817871"],"is_preprint":false},{"year":2018,"finding":"A single residue mutation I109A (I109^3.32) in transmembrane domain 3 of APJ converts a balanced receptor into a G protein-biased receptor: it retains full ligand binding and G protein activation but is defective in GRK recruitment, β-arrestin recruitment, and downstream receptor-mediated ERK activation; molecular dynamics simulations indicated that the Phe-13 residue of apelin rotates to form new hydrophobic interactions with TM3 residues (F110, M113), stabilizing the biased conformation.","method":"Site-directed mutagenesis, G protein activation assay, GRK/β-arrestin recruitment assays, ERK phosphorylation, molecular dynamics simulation","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — active-site mutagenesis with functional assays and MD simulation, single lab","pmids":["30409826"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structures of APLNR-Gi1 complexes bound to three agonists with divergent signaling profiles identified 'twin hotspots' in APLNR as key determinants for G protein vs. β-arrestin signaling bias; structure-guided design produced G protein-biased agonists WN353 and WN561, which showed superior therapeutic effects against cardiac hypertrophy with reduced adverse effects compared to established APLNR agonists.","method":"Cryo-EM structure determination, functional signaling assays, structure-based rational drug design, in vivo cardiac hypertrophy pathophysiology experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple cryo-EM structures, structure-guided mutagenesis and ligand design, in vivo functional validation","pmids":["38428423"],"is_preprint":false},{"year":2021,"finding":"APLN is produced by Sertoli cells in response to high glucose, and hyper-activated APLN/APJ signaling in diabetic testes suppresses carnitine production and represses cell adhesion gene expression in Sertoli cells, causing blood-testis barrier (BTB) structural dysfunction and impaired spermatogenesis; pharmacological blockade of APLN/APJ with ML221 ameliorated BTB damage and improved spermatogenesis in diabetic db/db mice and cultured human testes.","method":"STRT-seq single-cell transcriptomics of human diabetic testes, in vitro Sertoli cell culture with high glucose, pharmacological inhibition with ML221, db/db diabetic mouse model, human testis culture","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — single-cell transcriptomics, in vitro mechanistic studies, in vivo mouse model, human tissue validation","pmids":["36443325"],"is_preprint":false},{"year":2021,"finding":"Apelin induces cholangiocyte proliferation through Nox4/ROS/ERK-dependent signaling and activates hepatic stellate cells (HSCs) through intracellular ROS; APLN knockout or APJ antagonism (ML221) reduced bile duct ligation-induced cholangiocyte proliferation, liver inflammation, fibrosis, and angiogenesis in mice.","method":"Pharmacological inhibition (ML221, Nox4 inhibitor DPI, NAC, PD98059), APLN knockout mice, bile duct ligation model, Mdr2-/- mice, in vitro human biliary epithelial cells and HSC lines","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout and pharmacological inhibition, multiple inhibitors targeting specific pathway components, in vitro and in vivo models","pmids":["32964473"],"is_preprint":false},{"year":2020,"finding":"Elabela/Toddler and apelin bind differently to the apelin receptor: alanine scanning of ELA showed the C-terminus carries the key pharmacophore; Asp282/Asp284 of rat/human apelin receptor are critical for apelin binding and activity but are NOT involved in Elabela/Toddler activity, demonstrating distinct binding modes for the two endogenous ligands.","method":"Alanine scanning mutagenesis of ELA, site-directed mutagenesis of apelin receptor, binding affinity assays, cAMP inhibition assay, β-arrestin 2 recruitment assay in CHO cells","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic alanine scanning and receptor mutagenesis with functional assays, single lab","pmids":["32301550"],"is_preprint":false},{"year":2021,"finding":"Apelin-13, pGlu1-apelin-13, apelin-17, apelin-36, Elabela-21, and Elabela-32 exhibit distinct signaling profiles at APJ: all activate both G protein-dependent (cAMP inhibition, Ca2+ mobilization, early-phase ERK activation) and β-arrestin-dependent (GRKs, β-arrestin 1/2, AP2) pathways in a dose-dependent manner, but with different bias ratios; Elabela-32 showed >1000-fold bias to β-arrestin-dependent signaling, and apelin-17 was biased toward β-arrestin-dependent signaling.","method":"cAMP assay, Ca2+ mobilization, ERK phosphorylation, β-arrestin 1/2 recruitment assay, GRK assay, AP2 assay in APJ-expressing cells","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal signaling assays for multiple ligands, single lab","pmids":["33746758"],"is_preprint":false},{"year":2017,"finding":"Protamine binds the apelin receptor (APJ) with 390 nM affinity and acts as a full antagonist of both G protein and β-arrestin-dependent intracellular signaling; ex vivo and in vivo, protamine abolishes apelin-mediated angiogenesis, glucose tolerance improvement, and vasodilatation; protamine's APJ antagonist activity is fully reversed by heparin both in vitro and in vivo.","method":"Cell-based fluorescence microscopy screening assay for APJ antagonism, radioligand binding, cAMP and β-arrestin signaling assays, ex vivo angiogenesis and vasodilatation assays, in vivo glucose tolerance and angiogenesis tests, heparin reversal experiments","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — binding affinity quantified, multiple signaling assays, in vitro, ex vivo, and in vivo validation, heparin reversal mechanism established","pmids":["28242772"],"is_preprint":false},{"year":2016,"finding":"Apelin (APLN-13 and APLN-17) increases steroidogenesis (basal and IGF1-induced progesterone and estradiol) in human luteinized granulosa cells through activation of AKT and MAPK3/1 (ERK1/2) pathways and increased HSD3B protein expression; these effects are reversed by the APLNR antagonist ML221.","method":"RT-PCR, immunoblotting, pharmacological inhibitors of PI3K/Akt and MAPK, APJ antagonist ML221, steroid hormone ELISA","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibitors of specific pathways, receptor antagonist confirmation, single lab","pmids":["27683264"],"is_preprint":false},{"year":2017,"finding":"In bovine granulosa cells, APLN-13 and APLN-17 increase progesterone production via MAPK ERK1/2 and increase cell proliferation via AKT signaling (blocked by ML221); conversely, APLN-13 and APLN-17 arrest bovine oocytes at germinal vesicle stage during in vitro maturation, associated with decreased progesterone, inhibited ERK1/2 phosphorylation, and increased PRKA phosphorylation.","method":"In vitro bovine granulosa cell culture, in vitro oocyte maturation, pharmacological inhibition, immunoblotting for ERK1/2 and AKT, ML221 antagonist","journal":"Reproduction","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor antagonist and pathway inhibitor experiments, dual cell type mechanistic study, single lab","pmids":["28250234"],"is_preprint":false},{"year":2018,"finding":"Apelin promotes lymphangiogenesis: APJ is expressed in lymphatic endothelial cells (LECs) and activates apelinergic signaling; apelin treatment enhances LEC migration, protects against UV-induced apoptosis, increases spheroid formation, stimulates in vitro tube formation, and promotes in vivo lymphatic microvessel invasion; apelin overexpression in tumor cells increases intratumoral lymphangiogenesis and lymph node metastasis.","method":"APJ expression in LECs by immunofluorescence, in vitro migration, apoptosis, 3D spheroid, tube formation assays, in vivo matrigel plug assay, apelin-overexpressing tumor xenograft model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro assays and in vivo model, single lab","pmids":["24962866"],"is_preprint":false},{"year":2018,"finding":"Apelin deficiency in mice increases NADPH-stimulated superoxide levels in atria and slows atrial conduction velocities; apelin administration in mice with increased AF vulnerability reduced AF incidence/duration, prolonged atrial refractory periods, accelerated conduction velocity, and increased action potential duration; these electrophysiological effects were associated with increased atrial cardiomyocyte sodium currents.","method":"Apelin gene knockout mice, optical mapping of Langendorff-perfused isolated hearts, patch-clamp sodium current measurements, in vivo electrophysiology, NADPH oxidase activity assay","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with defined ionic and electrophysiological mechanism, multiple orthogonal methods","pmids":["32879139"],"is_preprint":false},{"year":2018,"finding":"The exerkine apelin is induced by muscle contraction; apelin or APLNR deficiency in mice causes age-dependent muscle dysfunction; restoration of apelin signaling enhances muscle function by triggering mitochondriogenesis, autophagy, and anti-inflammatory pathways in myofibers, and enhances regenerative capacity by targeting muscle stem cells.","method":"Apelin and APLNR knockout mice, apelin replacement strategies, exercise models, muscle stem cell assays, mitochondrial function assays, autophagy markers","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function in two models (apelin-/- and APLNR-/-), restoration experiments, multiple mechanistic readouts","pmids":["30061698"],"is_preprint":false},{"year":2015,"finding":"Apelin controls fetal glucose homeostasis: intravenous apelin injection in pregnant rats increases transplacental glucose transport; intraperitoneal apelin in neonates increases glucose uptake in lung and muscle; the apelinergic system is expressed at the fetoplacental interface and in multiple fetal tissues; placenta releases high amounts of apelin in late gestation ex vivo.","method":"Intravenous apelin administration in pregnant rats, radiolabeled glucose transplacental transport assay, intraperitoneal injection in neonates with tissue glucose uptake measurement, RT-PCR and immunostaining for tissue expression","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct in vivo apelin administration with functional metabolic readouts, single lab","pmids":["26631739"],"is_preprint":false},{"year":2017,"finding":"APJ is expressed at cellular junctions in human umbilical vein endothelial cells (HUVECs) and may associate with PECAM-1; siRNA-mediated silencing of APJ influences shear-induced cytoskeletal remodeling, cellular elasticity, motility, attachment, and distribution of adhesion complexes in endothelial cells.","method":"siRNA knockdown of APJ, immunofluorescence localization, atomic force microscopy for cellular elasticity, motility and adhesion assays in HUVECs under shear flow","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple functional readouts under physiological flow conditions, single lab","pmids":["29369349"],"is_preprint":false},{"year":2021,"finding":"Apelin improves endothelial cell dysfunction in diabetes by decreasing apoptosis, reducing adhesion molecule expression, and increasing proliferation, angiogenesis, and expression of E-cadherin, VEGFR2, and Tie-2; these effects were dependent on APJ and downstream NF-κB pathways, as confirmed by endothelial cell-specific APJ knockout mice.","method":"Endothelial cell-specific APJ knockout mice, cultured endothelial cell assays, NF-κB pathway analysis, in vivo diabetic cardiomyopathy model","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional knockout with pathway analysis, single lab","pmids":["33504680"],"is_preprint":false},{"year":2017,"finding":"Apelin is identified as a factor secreted by brain endothelial cells (by mass spectrometry proteomics) that maintains glioblastoma stem-like cell expansion; genetic and pharmacological targeting of the apelin receptor abrogates apelin- and endothelial-mediated expansion of glioblastoma stem-like cells in vitro and suppresses tumor growth in vivo.","method":"Mass spectrometry proteomic characterization of brain endothelial cell secretome, genetic apelin receptor targeting, competitive APJ antagonists, in vivo xenograft GBM model","journal":"Brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS identification plus genetic and pharmacological validation in vitro and in vivo, single lab","pmids":["29053791"],"is_preprint":false}],"current_model":"Apelin (APLN) is a peptide hormone processed from a 77-amino acid precursor that acts as an endogenous ligand for the G protein-coupled receptor APJ (APLNR), signaling through Gαi2/i3 (via rearrangement), Gαo, and Gαq to activate PI3K/Akt, MAPK/ERK, and AMPK pathways; it is transcriptionally induced by hypoxia via HIF-1α binding to an intronic HRE, by β-catenin in hepatocellular carcinoma, and by muscle contraction; apelin peptides are rapidly inactivated by ACE2 and neutral endopeptidase (NEP); crystal and cryo-EM structures of APJR revealed a two-site peptide binding mode and G protein stoichiometry-dependent signaling, with a key I109^3.32 residue controlling β-arrestin bias; apelin mediates cardiovascular protection (positive inotropy, NO-dependent vasodilatation, cardioprotection via RISK pathway/MPTP delay), promotes angiogenesis and lymphangiogenesis, controls cardiac precursor migration during gastrulation, enhances muscle mitochondriogenesis and autophagy, regulates cholangiocyte proliferation via Nox4/ROS/ERK, and modulates spermatogenesis by controlling Sertoli cell carnitine production and BTB integrity through the APLN/APJ axis."},"narrative":{"mechanistic_narrative":"Apelin (APLN) is a secreted peptide hormone, processed from a precursor into multiple bioactive forms (apelin-13, apelin-17, apelin-36), that acts as an endogenous agonist of the G-protein-coupled apelin receptor APJ/APLNR to coordinate cardiovascular, angiogenic, metabolic, and tissue-protective programs [PMID:15907343]. Engagement of APJ activates Gαi2/Gαi3 by molecular rearrangement and Gαo/Gαq by classical dissociation [PMID:25193074], driving PI3K/Akt and MAPK/ERK signaling that underlies its cellular effects, including cardioprotection against ischemia-reperfusion injury via the RISK pathway and delay of mitochondrial permeability transition pore opening [PMID:17694254]. Receptor activation is followed by GRK2-mediated, β-arrestin1-independent, clathrin/dynamin-dependent internalization, and downstream signaling bias is encoded structurally: the I109^3.32 residue of TM3 controls the balance between G protein and β-arrestin/GRK recruitment [PMID:30409826, PMID:27492965], and structure-guided design of G-protein-biased agonists yields improved efficacy against cardiac hypertrophy [PMID:38428423]. Crystal and cryo-EM structures defined a curved two-site peptide binding mode and stoichiometry-dependent G protein coupling, and showed that the second endogenous ligand Elabela/Toddler engages APJ through a distinct binding mode from apelin [PMID:28528775, PMID:35817871, PMID:32301550]. APLN is transcriptionally induced by hypoxia through HIF-1α binding to an intronic hypoxia-responsive element [PMID:18617693], by β-catenin in hepatocellular carcinoma [PMID:31410213], and by muscle contraction as an exerkine [PMID:30061698]. Functionally, apelin marks and drives sprouting (tip) endothelial cells in angiogenesis [PMID:25597280], promotes lymphangiogenesis [PMID:24962866], directs cardiac precursor migration during gastrulation [PMID:17336905], enhances muscle mitochondriogenesis and autophagy [PMID:30061698], and protects vasculature against aneurysm and oxidative injury [PMID:31189595, PMID:32879139]; its peptides are inactivated by ACE2 and by neutral endopeptidase [PMID:15907343, PMID:31189595]. The APLN/APJ axis also regulates Sertoli-cell carnitine production and blood-testis barrier integrity [PMID:36443325] and cholangiocyte proliferation through Nox4/ROS/ERK signaling [PMID:32964473], and apelin inhibition reduces tumor angiogenesis and glioblastoma stem-like cell expansion [PMID:31267692, PMID:29053791].","teleology":[{"year":2005,"claim":"Established that apelin peptides arise from a single gene to activate the GPCR APJ and are inactivated by ACE2, defining the core ligand-receptor-degradation axis.","evidence":"Biochemical/pharmacological characterization and review of experimental literature","pmids":["15907343"],"confidence":"High","gaps":["Did not resolve the G protein coupling specificity downstream of APJ","Tissue-specific roles of distinct peptide isoforms unaddressed"]},{"year":2007,"claim":"Defined a developmental requirement for apelin/APJ signaling in directing convergence of cardiac precursors, showing the axis is not merely a metabolic/cardiovascular modulator but a morphogenetic cue.","evidence":"Zebrafish loss- and gain-of-function genetics with in situ hybridization and confocal imaging of precursor migration","pmids":["17336905"],"confidence":"High","gaps":["Mammalian conservation of this gastrulation role not established here","Downstream effectors driving directional migration unidentified"]},{"year":2007,"claim":"Identified the signaling pathways for apelin cardioprotection, showing PI3K-Akt and ERK (RISK pathway) activation and MPTP delay mediate protection against ischemia-reperfusion.","evidence":"In vivo rodent I/R, Langendorff perfusion, isolated cardiomyocytes, PI3K and MEK inhibitors","pmids":["17694254"],"confidence":"High","gaps":["Receptor-proximal coupling to PI3K/ERK not dissected","Did not address chronic versus acute cardiac effects"]},{"year":2008,"claim":"Resolved how apelin transcription is regulated under stress, demonstrating HIF-1α directly binds an intronic HRE to induce apelin during hypoxia and that this drives endothelial proliferation and vessel regeneration.","evidence":"ChIP, reporter assays with mutagenesis, siRNA knockdown, zebrafish fin regeneration","pmids":["18617693"],"confidence":"High","gaps":["Other transcriptional inputs not yet mapped","Quantitative contribution of apelin to in vivo angiogenesis not isolated"]},{"year":2014,"claim":"Clarified the heterotrimeric G protein logic of APJ, showing Gαi2/Gαi3 activate by molecular rearrangement while Gαo/Gαq dissociate classically, refining how a single receptor produces diverse outputs.","evidence":"BRET/FRET in live HEK293 cells with fluorescent G-protein subunits","pmids":["25193074"],"confidence":"Medium","gaps":["Single-lab live-cell assay without structural confirmation","Functional consequences of rearrangement versus dissociation untested"]},{"year":2015,"claim":"Demonstrated apelin specifically marks and is functionally required in sprouting (tip) endothelial cells, downstream of VEGF-VEGFR2, distinguishing active from quiescent vasculature.","evidence":"Apln-CreER lineage tracing, tumor and ischemia models, genetic ablation","pmids":["25597280"],"confidence":"High","gaps":["Mechanism linking VEGFR2 to apelin transcription unresolved","Autocrine versus paracrine action on tip cells not distinguished"]},{"year":2015,"claim":"Identified Elabela/Toddler as a second endogenous APJ agonist that drives internalization, cAMP suppression, ERK activation, and angiogenesis, expanding the receptor's ligand repertoire.","evidence":"Reconstituted HEK293/CHO systems, cAMP, ERK, calcium assays, aortic ring relaxation","pmids":["25639753"],"confidence":"High","gaps":["Relative physiological roles of apelin versus Elabela unclear","Tissue contexts of preferential ligand use undefined"]},{"year":2015,"claim":"Extended apelin/APJ signaling into adipose thermogenesis and metabolism, showing PI3K/Akt and AMPK drive browning, mitochondrial biogenesis, and oxygen consumption.","evidence":"Adipocyte differentiation assays, pathway inhibitors, mouse model, mitochondrial function assays","pmids":["25931124"],"confidence":"Medium","gaps":["Single-lab finding","In vivo contribution to whole-body energy balance not quantified"]},{"year":2017,"claim":"Provided the first atomic-resolution view of APJ, revealing a curved two-site ligand binding mode and the residues governing apelin recognition.","evidence":"X-ray crystallography at 2.6 Å with a peptide mimetic, mutagenesis, MD simulation","pmids":["28528775"],"confidence":"High","gaps":["Captured with a mimetic rather than native peptide","G-protein-bound active state not resolved in this structure"]},{"year":2017,"claim":"Identified protamine as a full APJ antagonist whose activity is reversed by heparin, providing a pharmacological tool blocking both G protein and β-arrestin signaling and abolishing apelin-mediated angiogenesis and vasodilatation.","evidence":"Binding, cAMP and β-arrestin assays, ex vivo and in vivo functional tests, heparin reversal","pmids":["28242772"],"confidence":"High","gaps":["Specificity of protamine for APJ versus other targets not fully bounded","Therapeutic window not defined"]},{"year":2016,"claim":"Dissected APJ trafficking, showing apelin-induced internalization is GRK2- and dynamin/EPS15-dependent but β-arrestin1-independent, and that ERK desensitization occurs upstream of internalization.","evidence":"Dominant-negative constructs and fluorescence imaging of APJ internalization in HEK293","pmids":["27492965"],"confidence":"High","gaps":["Single-lab dominant-negative approach","Role of β-arrestin2 versus β-arrestin1 not separated"]},{"year":2018,"claim":"Mapped signaling bias to a single TM3 residue, showing I109A converts APJ into a G-protein-biased receptor defective in GRK and β-arrestin recruitment, establishing a structural basis for biased agonism.","evidence":"Site-directed mutagenesis, G protein/arrestin recruitment assays, ERK assay, MD simulation","pmids":["30409826"],"confidence":"High","gaps":["Single-lab mutagenesis","In vivo consequences of forced bias not tested in this study"]},{"year":2018,"claim":"Defined apelin as a contraction-induced exerkine essential for muscle homeostasis, with loss causing age-dependent dysfunction and restoration enhancing mitochondriogenesis, autophagy, and stem-cell-mediated regeneration.","evidence":"Apelin and APLNR knockout mice, replacement and exercise models, muscle stem cell and mitochondrial assays","pmids":["30061698"],"confidence":"High","gaps":["Direct molecular targets in myofibers versus stem cells not fully separated","Human translatability of the aging phenotype untested"]},{"year":2018,"claim":"Linked apelin to electrophysiological stability, showing apelin deficiency raises atrial superoxide and slows conduction while apelin reduces atrial fibrillation vulnerability via increased sodium currents.","evidence":"Apelin knockout mice, optical mapping, patch-clamp sodium currents, NADPH oxidase assay","pmids":["32879139"],"confidence":"High","gaps":["Receptor-to-sodium-channel coupling mechanism unresolved","Relevance to human atrial fibrillation not directly tested"]},{"year":2019,"claim":"Established apelin as a vasoprotective factor in aneurysm, identifying NEP as a degrading enzyme, showing apelin induces ACE2, and validating a NEP-resistant analog therapeutically.","evidence":"Apln knockout mice, Ang II-induced AAA, aortic SMC culture, peptide analog design, Ldlr-/- model","pmids":["31189595"],"confidence":"High","gaps":["Balance between ACE2 induction (protective) and ACE2 degradation of apelin not fully reconciled","Long-term analog safety not addressed"]},{"year":2019,"claim":"Showed APLN is a β-catenin transcriptional target in hepatocellular carcinoma that promotes tumor proliferation through PI3K/Akt-GSK3β-cyclin D1 signaling, connecting Wnt pathway activation to apelin-driven oncogenesis.","evidence":"β-catenin ChIP at APLN promoter, ectopic expression/knockdown, Western blot, xenograft","pmids":["31410213"],"confidence":"Medium","gaps":["Single-lab study","Autocrine versus paracrine APJ engagement in tumor not resolved"]},{"year":2022,"claim":"Captured fully active APJR-G protein complexes in both 2:1 and 1:1 stoichiometries, implicating receptor dimerization stoichiometry in shaping G protein coupling.","evidence":"Cryo-EM single-particle analysis with ELA and small-molecule ligands","pmids":["35817871"],"confidence":"High","gaps":["Physiological prevalence of dimeric versus monomeric signaling in cells unknown","Functional output differences between stoichiometries not directly measured"]},{"year":2024,"claim":"Identified structural 'twin hotspots' governing G protein versus β-arrestin bias and used them to design G-protein-biased agonists with superior anti-hypertrophic efficacy, translating structural insight into improved therapeutics.","evidence":"Multiple cryo-EM structures, signaling assays, structure-based design, in vivo cardiac hypertrophy models","pmids":["38428423"],"confidence":"High","gaps":["Long-term in vivo safety of biased agonists not established","Generalizability of hotspots to other peptide GPCRs untested"]},{"year":2020,"claim":"Demonstrated distinct binding determinants for the two endogenous ligands, showing Asp282/Asp284 are critical for apelin but not Elabela, mechanistically separating their receptor engagement.","evidence":"Alanine scanning of ELA, receptor mutagenesis, binding, cAMP, β-arrestin2 assays in CHO cells","pmids":["32301550"],"confidence":"High","gaps":["Single-lab study","Structural basis of differential engagement not visualized here"]},{"year":2021,"claim":"Catalogued ligand-specific bias across apelin and Elabela isoforms, showing all engage both G protein and β-arrestin pathways but with markedly different bias ratios.","evidence":"cAMP, Ca2+, ERK, β-arrestin1/2, GRK, AP2 assays in APJ cells","pmids":["33746758"],"confidence":"Medium","gaps":["Single-lab quantitative bias values","Physiological relevance of extreme bias ratios untested"]},{"year":2021,"claim":"Revealed a pathological APLN/APJ role in diabetic testis, where Sertoli-cell apelin suppresses carnitine production and adhesion genes to disrupt the blood-testis barrier, reversible by antagonist ML221.","evidence":"Single-cell transcriptomics of human diabetic testes, Sertoli cell culture, db/db mice, human testis culture, ML221","pmids":["36443325"],"confidence":"High","gaps":["Direct transcriptional link between APJ signaling and adhesion gene repression not fully mapped","Reversibility window in human disease unknown"]},{"year":2021,"claim":"Defined apelin's profibrotic role in liver, driving cholangiocyte proliferation through Nox4/ROS/ERK and activating hepatic stellate cells via ROS, with knockout or antagonism reducing fibrosis.","evidence":"APLN knockout mice, bile duct ligation, Mdr2-/- mice, pathway inhibitors, biliary and HSC cultures","pmids":["32964473"],"confidence":"High","gaps":["Source of apelin within injured liver not fully resolved","Crosstalk with other fibrogenic signals undefined"]},{"year":null,"claim":"How tissue context selects among apelin's many divergent outputs—protective versus profibrotic versus pro-tumorigenic—and how ligand identity, receptor bias, and stoichiometry are integrated in vivo remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking biased agonism to specific physiological versus pathological outcomes","Endogenous peptide isoform balance in different tissues uncharacterized","Predictive rules for therapeutic agonist versus antagonist choice not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,6,7,20]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[9,15]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,26,30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,2,9]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,5,24]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[1,26]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,12,13,17,18]}],"complexes":[],"partners":["APLNR","ACE2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9ULZ1","full_name":"Apelin","aliases":["APJ endogenous ligand"],"length_aa":77,"mass_kda":8.6,"function":"Peptide hormone that functions as endogenous ligand for the G-protein-coupled apelin receptor (APLNR/APJ), that plays a role in cadiovascular homeostasis (PubMed:10525157, PubMed:22810587, PubMed:35817871, PubMed:38428423). Functions as a balanced agonist activating both G(i) protein pathway and beta-arrestin pathway of APLNR (PubMed:22810587, PubMed:38428423). Downstream G proteins activation, apelin can inhibit cAMP production and activate key intracellular effectors such as ERKs (PubMed:22810587, PubMed:35817871, PubMed:38428423). On the other hand, APLNR activation induces beta-arrestin recruitment to the membrane leading to desensitization and internalization of the receptor (PubMed:22810587, PubMed:38428423). Apelin blunts cardiac hypertrophic induction from APLNR on response to pathological stimuli, but also induces myocardial hypertrophy under normal conditions (PubMed:22810587, PubMed:38428423). Apelin-36 dissociates more hardly than (pyroglu)apelin-13 from APLNR (By similarity). Involved in the regulation of cardiac precursor cell movements during gastrulation and heart morphogenesis (By similarity). Has an inhibitory effect on cytokine production in response to T-cell receptor/CD3 cross-linking; the oral intake of apelin in the colostrum and the milk might therefore modulate immune responses in neonates (By similarity). Plays a role in early coronary blood vessels formation (By similarity). Mediates myocardial contractility in an ERK1/2-dependent manner (By similarity). May also have a role in the central control of body fluid homeostasis by influencing vasopressin release and drinking behavior (By similarity) (Microbial infection) Endogenous ligand for the apelin receptor (APLNR), an alternative coreceptor with CD4 for HIV-1 infection (PubMed:11090199). Inhibits HIV-1 entry in cells coexpressing CD4 and APLNR (PubMed:11090199). Apelin-36 has a greater inhibitory activity on HIV infection than other synthetic apelin derivatives (PubMed:11090199)","subcellular_location":"Secreted; Secreted, extracellular space","url":"https://www.uniprot.org/uniprotkb/Q9ULZ1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APLN","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APLN","total_profiled":1310},"omim":[{"mim_id":"300297","title":"APELIN; APLN","url":"https://www.omim.org/entry/300297"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":29.4},{"tissue":"placenta","ntpm":50.8}],"url":"https://www.proteinatlas.org/search/APLN"},"hgnc":{"alias_symbol":["apelin","XNPEP2"],"prev_symbol":[]},"alphafold":{"accession":"Q9ULZ1","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9ULZ1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9ULZ1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9ULZ1-F1-predicted_aligned_error_v6.png","plddt_mean":67.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APLN","jax_strain_url":"https://www.jax.org/strain/search?query=APLN"},"sequence":{"accession":"Q9ULZ1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9ULZ1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9ULZ1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9ULZ1"}},"corpus_meta":[{"pmid":"15907343","id":"PMC_15907343","title":"Emerging roles of apelin in biology and medicine.","date":"2005","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15907343","citation_count":326,"is_preprint":false},{"pmid":"30061698","id":"PMC_30061698","title":"The exerkine apelin reverses age-associated sarcopenia.","date":"2018","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30061698","citation_count":316,"is_preprint":false},{"pmid":"23943882","id":"PMC_23943882","title":"The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis.","date":"2013","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23943882","citation_count":269,"is_preprint":false},{"pmid":"21725702","id":"PMC_21725702","title":"Apelin, diabetes, and obesity.","date":"2011","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/21725702","citation_count":222,"is_preprint":false},{"pmid":"18617693","id":"PMC_18617693","title":"Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis.","date":"2008","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/18617693","citation_count":215,"is_preprint":false},{"pmid":"29875677","id":"PMC_29875677","title":"The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer.","date":"2018","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29875677","citation_count":191,"is_preprint":false},{"pmid":"17694254","id":"PMC_17694254","title":"Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury.","date":"2007","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17694254","citation_count":184,"is_preprint":false},{"pmid":"25639753","id":"PMC_25639753","title":"Elabela-apelin receptor signaling pathway is functional in mammalian systems.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25639753","citation_count":170,"is_preprint":false},{"pmid":"18272138","id":"PMC_18272138","title":"The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18272138","citation_count":150,"is_preprint":false},{"pmid":"15601620","id":"PMC_15601620","title":"Apelin signalling: a promising pathway from cloning to pharmacology.","date":"2005","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/15601620","citation_count":142,"is_preprint":false},{"pmid":"17336905","id":"PMC_17336905","title":"Apelin and its receptor control heart field formation during zebrafish gastrulation.","date":"2007","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/17336905","citation_count":142,"is_preprint":false},{"pmid":"29807055","id":"PMC_29807055","title":"Vascular effects of apelin: Mechanisms and therapeutic potential.","date":"2018","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29807055","citation_count":132,"is_preprint":false},{"pmid":"18583184","id":"PMC_18583184","title":"The role of apelin in cardiovascular function and heart failure.","date":"2008","source":"European journal of heart failure","url":"https://pubmed.ncbi.nlm.nih.gov/18583184","citation_count":127,"is_preprint":false},{"pmid":"26143239","id":"PMC_26143239","title":"Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.","date":"2015","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26143239","citation_count":115,"is_preprint":false},{"pmid":"28528775","id":"PMC_28528775","title":"Structural Basis for Apelin Control of the Human Apelin Receptor.","date":"2017","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/28528775","citation_count":108,"is_preprint":false},{"pmid":"29750964","id":"PMC_29750964","title":"Review: Apelin in disease.","date":"2018","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29750964","citation_count":107,"is_preprint":false},{"pmid":"24055369","id":"PMC_24055369","title":"Apelin and its receptor APJ in cardiovascular diseases.","date":"2013","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24055369","citation_count":105,"is_preprint":false},{"pmid":"25597280","id":"PMC_25597280","title":"Genetic targeting of sprouting angiogenesis using Apln-CreER.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25597280","citation_count":105,"is_preprint":false},{"pmid":"20584856","id":"PMC_20584856","title":"Translational promise of the apelin--APJ system.","date":"2010","source":"Heart (British Cardiac Society)","url":"https://pubmed.ncbi.nlm.nih.gov/20584856","citation_count":102,"is_preprint":false},{"pmid":"16733497","id":"PMC_16733497","title":"Apelin and visfatin: unique \"beneficial\" adipokines upregulated in obesity?","date":"2006","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/16733497","citation_count":98,"is_preprint":false},{"pmid":"25931124","id":"PMC_25931124","title":"Apelin Enhances Brown Adipogenesis and Browning of White Adipocytes.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25931124","citation_count":93,"is_preprint":false},{"pmid":"32128601","id":"PMC_32128601","title":"Apelin/APJ system: an emerging therapeutic target for respiratory diseases.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32128601","citation_count":91,"is_preprint":false},{"pmid":"31267692","id":"PMC_31267692","title":"Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy.","date":"2019","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31267692","citation_count":91,"is_preprint":false},{"pmid":"28167898","id":"PMC_28167898","title":"Temporal Expression of Apelin/Apelin Receptor in Ischemic Stroke and its Therapeutic Potential.","date":"2017","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28167898","citation_count":85,"is_preprint":false},{"pmid":"22820556","id":"PMC_22820556","title":"Neuroprotection of apelin and its signaling pathway.","date":"2012","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/22820556","citation_count":85,"is_preprint":false},{"pmid":"33679444","id":"PMC_33679444","title":"The Role of Apelin/Apelin Receptor in Energy Metabolism and Water Homeostasis: A Comprehensive Narrative Review.","date":"2021","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33679444","citation_count":82,"is_preprint":false},{"pmid":"34389827","id":"PMC_34389827","title":"The therapeutic potential of apelin in kidney disease.","date":"2021","source":"Nature reviews. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/34389827","citation_count":81,"is_preprint":false},{"pmid":"25652330","id":"PMC_25652330","title":"Effects of apelin on the cardiovascular system.","date":"2015","source":"Heart failure reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25652330","citation_count":81,"is_preprint":false},{"pmid":"29053791","id":"PMC_29053791","title":"Pharmacological targeting of apelin impairs glioblastoma growth.","date":"2017","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29053791","citation_count":79,"is_preprint":false},{"pmid":"26007641","id":"PMC_26007641","title":"Apelin receptors: From signaling to antidiabetic strategy.","date":"2015","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26007641","citation_count":78,"is_preprint":false},{"pmid":"35355561","id":"PMC_35355561","title":"The Role of Apelin-APJ System in Diabetes and Obesity.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35355561","citation_count":77,"is_preprint":false},{"pmid":"24962866","id":"PMC_24962866","title":"Apelin promotes lymphangiogenesis and lymph node metastasis.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24962866","citation_count":77,"is_preprint":false},{"pmid":"25815211","id":"PMC_25815211","title":"The ACE2/Apelin Signaling, MicroRNAs, and Hypertension.","date":"2015","source":"International journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/25815211","citation_count":75,"is_preprint":false},{"pmid":"29684595","id":"PMC_29684595","title":"Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.","date":"2018","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/29684595","citation_count":75,"is_preprint":false},{"pmid":"17128405","id":"PMC_17128405","title":"Modulation of apelin and APJ receptor in normal and preeclampsia-complicated placentas.","date":"2007","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/17128405","citation_count":74,"is_preprint":false},{"pmid":"37956047","id":"PMC_37956047","title":"Targeting the apelin system for the treatment of cardiovascular diseases.","date":"2023","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/37956047","citation_count":73,"is_preprint":false},{"pmid":"27083318","id":"PMC_27083318","title":"Apelin/APJ system and cancer.","date":"2016","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27083318","citation_count":73,"is_preprint":false},{"pmid":"22140623","id":"PMC_22140623","title":"Apelin and pulmonary hypertension.","date":"2011","source":"Pulmonary circulation","url":"https://pubmed.ncbi.nlm.nih.gov/22140623","citation_count":72,"is_preprint":false},{"pmid":"29977292","id":"PMC_29977292","title":"Apelin in Reproductive Physiology and Pathology of Different Species: A Critical Review.","date":"2018","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29977292","citation_count":71,"is_preprint":false},{"pmid":"16563531","id":"PMC_16563531","title":"Apelin and its receptor are expressed in human osteoblasts.","date":"2006","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/16563531","citation_count":69,"is_preprint":false},{"pmid":"27683264","id":"PMC_27683264","title":"Apelin (APLN) and Apelin Receptor (APLNR) in Human Ovary: Expression, Signaling, and Regulation of Steroidogenesis in Primary Human Luteinized Granulosa Cells.","date":"2016","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/27683264","citation_count":67,"is_preprint":false},{"pmid":"35605524","id":"PMC_35605524","title":"Apelin/APJ system in inflammation.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35605524","citation_count":62,"is_preprint":false},{"pmid":"30718358","id":"PMC_30718358","title":"Targeting APLN/APLNR Improves Antiangiogenic Efficiency and Blunts Proinvasive Side Effects of VEGFA/VEGFR2 Blockade in Glioblastoma.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30718358","citation_count":62,"is_preprint":false},{"pmid":"31410213","id":"PMC_31410213","title":"APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31410213","citation_count":60,"is_preprint":false},{"pmid":"32087570","id":"PMC_32087570","title":"Role of Apelin/APJ axis in cancer development and progression.","date":"2020","source":"Advances in medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32087570","citation_count":59,"is_preprint":false},{"pmid":"36443325","id":"PMC_36443325","title":"Targeting APLN/APJ restores blood-testis barrier and improves spermatogenesis in murine and human diabetic models.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36443325","citation_count":58,"is_preprint":false},{"pmid":"35817871","id":"PMC_35817871","title":"Structural insight into apelin receptor-G protein stoichiometry.","date":"2022","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35817871","citation_count":55,"is_preprint":false},{"pmid":"23588025","id":"PMC_23588025","title":"Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis.","date":"2013","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/23588025","citation_count":55,"is_preprint":false},{"pmid":"31189595","id":"PMC_31189595","title":"Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31189595","citation_count":55,"is_preprint":false},{"pmid":"27894959","id":"PMC_27894959","title":"Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.","date":"2016","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/27894959","citation_count":52,"is_preprint":false},{"pmid":"24990699","id":"PMC_24990699","title":"Apelin/APJ system: a promising therapy target for hypertension.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24990699","citation_count":48,"is_preprint":false},{"pmid":"25447414","id":"PMC_25447414","title":"The protective effect of apelin on ischemia/reperfusion injury.","date":"2014","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/25447414","citation_count":47,"is_preprint":false},{"pmid":"26436483","id":"PMC_26436483","title":"Apelin/APJ signaling in hypoxia-related diseases.","date":"2015","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26436483","citation_count":46,"is_preprint":false},{"pmid":"32231577","id":"PMC_32231577","title":"The Apelin/APJ System in Psychosis and Neuropathy.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32231577","citation_count":44,"is_preprint":false},{"pmid":"28250234","id":"PMC_28250234","title":"Apelin (APLN) regulates progesterone secretion and oocyte maturation in bovine ovarian cells.","date":"2017","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28250234","citation_count":43,"is_preprint":false},{"pmid":"27979574","id":"PMC_27979574","title":"Apelin/APJ system: A bifunctional target for cardiac hypertrophy.","date":"2016","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/27979574","citation_count":43,"is_preprint":false},{"pmid":"27258138","id":"PMC_27258138","title":"Apelin-13 in blood pressure regulation and cardiovascular disease.","date":"2016","source":"Current opinion in nephrology and hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/27258138","citation_count":40,"is_preprint":false},{"pmid":"30910349","id":"PMC_30910349","title":"Elabela and Apelin actions in healthy and pathological pregnancies.","date":"2019","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30910349","citation_count":39,"is_preprint":false},{"pmid":"32545380","id":"PMC_32545380","title":"Apelin Controls Angiogenesis-Dependent Glioblastoma Growth.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32545380","citation_count":39,"is_preprint":false},{"pmid":"32964473","id":"PMC_32964473","title":"The Apelin-Apelin Receptor Axis Triggers Cholangiocyte Proliferation and Liver Fibrosis During Mouse Models of Cholestasis.","date":"2021","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32964473","citation_count":37,"is_preprint":false},{"pmid":"34801627","id":"PMC_34801627","title":"Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists.","date":"2021","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/34801627","citation_count":37,"is_preprint":false},{"pmid":"30390294","id":"PMC_30390294","title":"Function and regulation of apelin/APJ system in digestive physiology and pathology.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30390294","citation_count":35,"is_preprint":false},{"pmid":"26528040","id":"PMC_26528040","title":"The Apelin-APJ System in the Evolution of Heart Failure.","date":"2015","source":"Clujul medical (1957)","url":"https://pubmed.ncbi.nlm.nih.gov/26528040","citation_count":35,"is_preprint":false},{"pmid":"28407045","id":"PMC_28407045","title":"Novel pathogenesis: regulation of apoptosis by Apelin/APJ system.","date":"2017","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/28407045","citation_count":35,"is_preprint":false},{"pmid":"38428423","id":"PMC_38428423","title":"Structure-based design of non-hypertrophic apelin receptor modulator.","date":"2024","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/38428423","citation_count":33,"is_preprint":false},{"pmid":"35011661","id":"PMC_35011661","title":"Apelin, APJ, and ELABELA: Role in Placental Function, Pregnancy, and Foetal Development-An Overview.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35011661","citation_count":32,"is_preprint":false},{"pmid":"26631739","id":"PMC_26631739","title":"Apelin Controls Fetal and Neonatal Glucose Homeostasis and Is Altered by Maternal Undernutrition.","date":"2015","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26631739","citation_count":32,"is_preprint":false},{"pmid":"27492965","id":"PMC_27492965","title":"Agonist-induced internalization and desensitization of the apelin receptor.","date":"2016","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27492965","citation_count":30,"is_preprint":false},{"pmid":"33640616","id":"PMC_33640616","title":"Neuroprotective gain of Apelin/APJ system.","date":"2021","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/33640616","citation_count":29,"is_preprint":false},{"pmid":"20615122","id":"PMC_20615122","title":"Effect of apelin-apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool?","date":"2010","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/20615122","citation_count":29,"is_preprint":false},{"pmid":"33504680","id":"PMC_33504680","title":"Apelin/APJ relieve diabetic cardiomyopathy by reducing microvascular dysfunction.","date":"2021","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33504680","citation_count":28,"is_preprint":false},{"pmid":"32835696","id":"PMC_32835696","title":"Apelin/Apelin receptor: A new therapeutic target in Polycystic Ovary Syndrome.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32835696","citation_count":27,"is_preprint":false},{"pmid":"36745269","id":"PMC_36745269","title":"Neuroprotective Roles of Apelin-13 in Neurological Diseases.","date":"2023","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/36745269","citation_count":27,"is_preprint":false},{"pmid":"33746758","id":"PMC_33746758","title":"The Effects of Apelin and Elabela Ligands on Apelin Receptor Distinct Signaling Profiles.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33746758","citation_count":27,"is_preprint":false},{"pmid":"34880830","id":"PMC_34880830","title":"Apelin and Vasopressin: The Yin and Yang of Water Balance.","date":"2021","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34880830","citation_count":26,"is_preprint":false},{"pmid":"36378421","id":"PMC_36378421","title":"Apelin/APJ system: an emerging therapeutic target for neurological diseases.","date":"2022","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/36378421","citation_count":26,"is_preprint":false},{"pmid":"32484774","id":"PMC_32484774","title":"Apelin/Apelin Receptor System: Molecular Characteristics, Physiological Roles, and Prospects as a Target for Disease Prevention and Pharmacotherapy.","date":"2021","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32484774","citation_count":26,"is_preprint":false},{"pmid":"28242772","id":"PMC_28242772","title":"Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28242772","citation_count":26,"is_preprint":false},{"pmid":"28620355","id":"PMC_28620355","title":"Role of the Vasopressin/Apelin Balance and Potential Use of Metabolically Stable Apelin Analogs in Water Metabolism Disorders.","date":"2017","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28620355","citation_count":26,"is_preprint":false},{"pmid":"20099713","id":"PMC_20099713","title":"Apelin and its receptor APJ in human aortic valve stenosis.","date":"2009","source":"The Journal of heart valve disease","url":"https://pubmed.ncbi.nlm.nih.gov/20099713","citation_count":26,"is_preprint":false},{"pmid":"25193074","id":"PMC_25193074","title":"Dynamics of apelin receptor/G protein coupling in living cells.","date":"2014","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/25193074","citation_count":25,"is_preprint":false},{"pmid":"32562701","id":"PMC_32562701","title":"Apelin-potential therapy for COVID-19?","date":"2020","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/32562701","citation_count":24,"is_preprint":false},{"pmid":"33838166","id":"PMC_33838166","title":"The therapeutic potentials of apelin in obesity-associated diseases.","date":"2021","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33838166","citation_count":24,"is_preprint":false},{"pmid":"30783205","id":"PMC_30783205","title":"Apelin and apelin receptor expression in renal cell carcinoma.","date":"2019","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30783205","citation_count":24,"is_preprint":false},{"pmid":"32301550","id":"PMC_32301550","title":"Elabela/Toddler and apelin bind differently to the apelin receptor.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32301550","citation_count":23,"is_preprint":false},{"pmid":"32066307","id":"PMC_32066307","title":"A patent review of apelin receptor (APJR) modulators (2014-2019).","date":"2020","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/32066307","citation_count":23,"is_preprint":false},{"pmid":"25060841","id":"PMC_25060841","title":"Apelin and G212A apelin receptor gene polymorphism in obese and diabese youth.","date":"2014","source":"Pediatric obesity","url":"https://pubmed.ncbi.nlm.nih.gov/25060841","citation_count":23,"is_preprint":false},{"pmid":"33161074","id":"PMC_33161074","title":"Apelin-13 prevents hippocampal synaptic plasticity impairment in Parkinsonism rats.","date":"2020","source":"Journal of chemical neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/33161074","citation_count":23,"is_preprint":false},{"pmid":"35598689","id":"PMC_35598689","title":"The Apelin/APLNR system modulates tumor immune response by reshaping the tumor microenvironment.","date":"2022","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/35598689","citation_count":22,"is_preprint":false},{"pmid":"29369349","id":"PMC_29369349","title":"The apelin receptor influences biomechanical and morphological properties of endothelial cells.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29369349","citation_count":22,"is_preprint":false},{"pmid":"21775567","id":"PMC_21775567","title":"Apelin gene polymorphism influences apelin expression and obesity phenotypes in Chinese women.","date":"2011","source":"The American journal of clinical nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/21775567","citation_count":22,"is_preprint":false},{"pmid":"37562237","id":"PMC_37562237","title":"Therapeutic potential of apelin and Elabela in cardiovascular disease.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37562237","citation_count":20,"is_preprint":false},{"pmid":"33797707","id":"PMC_33797707","title":"A network map of apelin-mediated signaling.","date":"2021","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/33797707","citation_count":20,"is_preprint":false},{"pmid":"31595589","id":"PMC_31595589","title":"Evaluation of serum apelin-13 and apelin-36 concentrations in preeclamptic pregnancies.","date":"2019","source":"The journal of obstetrics and gynaecology research","url":"https://pubmed.ncbi.nlm.nih.gov/31595589","citation_count":20,"is_preprint":false},{"pmid":"34608073","id":"PMC_34608073","title":"Targeting the elabela/apelin-apelin receptor axis as a novel therapeutic approach for hypertension.","date":"2022","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34608073","citation_count":19,"is_preprint":false},{"pmid":"32879139","id":"PMC_32879139","title":"Apelin increases atrial conduction velocity, refractoriness, and prevents inducibility of atrial fibrillation.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32879139","citation_count":19,"is_preprint":false},{"pmid":"35177945","id":"PMC_35177945","title":"Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: An Update.","date":"2022","source":"Clinical medicine insights. Endocrinology and diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/35177945","citation_count":18,"is_preprint":false},{"pmid":"30409826","id":"PMC_30409826","title":"GPCR structure and function relationship: identification of a biased apelin receptor mutant.","date":"2018","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/30409826","citation_count":18,"is_preprint":false},{"pmid":"28248533","id":"PMC_28248533","title":"The effect of apelin on the functions of peritoneal macrophages.","date":"2017","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/28248533","citation_count":18,"is_preprint":false},{"pmid":"35355567","id":"PMC_35355567","title":"Apelin and Apelin Receptor in Follicular Granulosa Cells of Buffalo Ovaries: Expression and Regulation of Steroidogenesis.","date":"2022","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35355567","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43021,"output_tokens":7998,"usd":0.124517,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17798,"output_tokens":6304,"usd":0.123295,"stage2_stop_reason":"end_turn"},"total_usd":0.247812,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"Apelin peptides are derived from a single gene and activate the 7-transmembrane G-protein-coupled receptor APJ; apelin peptides also represent substrates for ACE2 carboxypeptidase, which cleaves and inactivates them.\",\n      \"method\": \"Biochemical/pharmacological characterization; review of experimental literature\",\n      \"journal\": \"Pharmacology & therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple labs, consistent with broad corpus\",\n      \"pmids\": [\"15907343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Hypoxia induces apelin expression in endothelial and vascular smooth muscle cells via HIF-1α binding to a hypoxia-responsive element (HRE) located within the first intron (+813/+826) of the human apelin gene; siRNA knockdown of HIF-1α abolished hypoxia-induced apelin expression; apelin or APJ receptor knockdown inhibited hypoxia-induced endothelial cell proliferation in vitro and vessel regeneration in zebrafish.\",\n      \"method\": \"Transient transfection reporter assay, chromatin immunoprecipitation (ChIP), siRNA knockdown, in vivo zebrafish fin regeneration model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP demonstrating HIF-1α binding to endogenous locus, reporter assays with mutagenesis, functional knockdown in vitro and in vivo\",\n      \"pmids\": [\"18617693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Apelin-13 and apelin-36 produce cardioprotection against ischemia-reperfusion injury by activating the PI3K-Akt and p44/42 MAPK (RISK pathway) and delaying mitochondrial permeability transition pore (MPTP) opening; pharmacological inhibition of PI3K (LY294002) or MEK (UO126/MEK inhibitor 1) abolished the protective effects.\",\n      \"method\": \"In vivo open-chest rodent I/R model, in vitro Langendorff perfusion and isolated cardiomyocytes, Western blot for pathway activation, pharmacological inhibitors of PI3K and MEK\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal models (in vivo and in vitro), pathway inhibitor experiments, replicated across infarct size and MPTP assays\",\n      \"pmids\": [\"17694254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Zebrafish apelin (ligand) and its receptor Agtrl1b (APJ homolog) control heart field formation during gastrulation by directing convergence of cardiac precursors from lateral plate mesoderm toward the midline; reduced or excess Apelin/Agtrl1b function caused deficiency of cardiac precursors and heart defects.\",\n      \"method\": \"Zebrafish loss-of-function and gain-of-function genetic experiments, in situ hybridization, confocal microscopy of cardiac precursor migration\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function and gain-of-function with defined cardiac morphogenetic phenotype in zebrafish ortholog\",\n      \"pmids\": [\"17336905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Apelin-APJ signaling promotes brown adipocyte differentiation and browning of white adipocytes by increasing expression of brown adipogenic and thermogenic transcription factors via PI3K/Akt and AMPK signaling pathways; apelin also increases mitochondrial biogenesis, PGC1α and UCP1 expression, and oxygen consumption.\",\n      \"method\": \"In vitro adipocyte differentiation assays, PI3K/Akt and AMPK pathway pharmacological inhibitors, in vivo mouse model, gene expression and mitochondrial function assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo data with pathway inhibitors, single lab\",\n      \"pmids\": [\"25931124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"APLN is robustly expressed in sprouting (tip) endothelial cells during angiogenesis and is re-activated in adult endothelial cells after ischemia; genetic ablation using Apln-CreER specifically labels sprouting but not quiescent vasculature, and abolishment of VEGF-VEGFR2 signaling reduced APLN expression in sprouting endothelium.\",\n      \"method\": \"Apln-CreER genetic lineage tracing mouse model, tumor angiogenesis and ischemia models, genetic ablation of sprouting endothelial cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic lineage tracing with functional consequence, multiple pathological models\",\n      \"pmids\": [\"25597280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Elabela (ELA)/Toddler activates the apelin receptor (APJ) in mammalian cells, causing receptor internalization, suppression of cAMP production (EC50 ~11 nM), ERK1/2 phosphorylation (EC50 ~14 nM), and weak intracellular calcium mobilization; ELA also induces angiogenesis in endothelial cells and relaxes mouse aortic blood vessels.\",\n      \"method\": \"Reconstituted HEK293 and CHO cell systems with GFP-APJ fusion, cAMP assay, ERK1/2 phosphorylation assay, calcium mobilization, aortic ring relaxation ex vivo\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reconstituted receptor signaling with quantified EC50 values, multiple orthogonal assays, ex vivo functional validation\",\n      \"pmids\": [\"25639753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of human apelin receptor (APJR) at 2.6 Å resolution in complex with a 17-amino acid apelin mimetic peptide revealed a lactam-constrained, curved two-site ligand binding mode; mutation analysis and molecular dynamics simulations with apelin-13 identified key binding residues for apelin recognition and specificity.\",\n      \"method\": \"X-ray crystallography (2.6 Å), site-directed mutagenesis, molecular dynamics simulation\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mutagenesis and MD validation\",\n      \"pmids\": [\"28528775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Apelin-induced internalization of APJ occurs via clathrin-coated vesicles (CCVs) in a GRK2-mediated phosphorylation-dependent, β-arrestin1-independent, EPS15- and dynamin-dependent manner; [Pyr1]apelin-13 stimulation also causes rapid desensitization of APJ-mediated ERK1/2 (ppERK1/2) signaling through upstream APJ-specific adaptive changes rather than internalization.\",\n      \"method\": \"Dominant-negative mutant cDNA constructs (GRK2, β-arrestin1, EPS15, dynamin), semi-automated fluorescence imaging of HA-tagged APJ internalization in HEK293 cells, ERK1/2 phosphorylation assays\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative constructs for mechanistic dissection, multiple trafficking components tested, single lab\",\n      \"pmids\": [\"27492965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Apelin-13 stimulation of APJ activates Gαi2 and Gαi3 through molecular rearrangement (rather than classical dissociation), while Gαo and Gαq are activated through classical dissociation; Gαi1 showed little change after apelin-13 stimulation.\",\n      \"method\": \"BRET and FRET in live HEK293 cells expressing APJ and fluorescent G-protein subunits\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell BRET/FRET measurements, single lab\",\n      \"pmids\": [\"25193074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Apelin and APJ are expressed in human osteoblasts; apelin stimulates osteoblast proliferation via APJ-dependent activation of PI3K/Akt (but not JNK, p38, or ERK1/2); siRNA-mediated APJ knockdown and LY294002 (PI3K inhibitor) abolished apelin-induced proliferation.\",\n      \"method\": \"RT-PCR, Western blot, siRNA knockdown of APJ, pharmacological PI3K inhibitor (LY294002), cell proliferation assay\",\n      \"journal\": \"Regulatory peptides\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with pathway inhibitor, single lab, two orthogonal methods\",\n      \"pmids\": [\"16563531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Apelin inhibition reduces tumor angiogenesis, remodels the tumor microenvironment by reducing polymorphonuclear myeloid-derived suppressor cell infiltration, and prevents resistance to anti-angiogenic RTK inhibitor therapy; apelin loss alone accelerated tumor cell invasion, but combined apelin/VEGFR2 blockade was synergistically effective.\",\n      \"method\": \"Genetic knockout and pharmacological inhibition of apelin/APLNR in mammary and lung cancer mouse models, tumor microenvironment analysis\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic and pharmacological models, multiple tumor types, single lab\",\n      \"pmids\": [\"31267692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"APLN is transcriptionally upregulated by active β-catenin, which binds to the APLN promoter to induce transcription in hepatocellular carcinoma; APLN activates PI3K/Akt via APLN receptor, leading to increased p-GSK3β and cyclin D1, promoting G1/S cell cycle progression and inhibiting apoptosis.\",\n      \"method\": \"β-catenin ChIP at APLN promoter, ectopic expression and siRNA knockdown, Western blot for PI3K/Akt pathway components, xenograft mouse model\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for upstream regulator, mechanistic pathway analysis with knockdown, in vivo xenograft, single lab\",\n      \"pmids\": [\"31410213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"APLN protects against abdominal aortic aneurysm by preventing smooth muscle cell apoptosis and oxidative stress; APLN induces ACE2 expression in the vasculature; neutral endopeptidase (NEP) is a major enzyme that metabolizes and inactivates APLN-17 in human AAA tissue; a NEP-resistant APLN-17 analog (APLN-NMeLeu9-A2) ameliorated Ang II-mediated AAA in mice.\",\n      \"method\": \"Apln knockout mice, Ang II-induced AAA model, cultured murine and human aortic SMCs, pharmacological and genetic approaches, peptide analog design and synthesis, high-fat diet Ldlr-/- mouse model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple genetic models, in vitro mechanistic work, identification of degrading enzyme, therapeutic analog validation in vivo\",\n      \"pmids\": [\"31189595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM structures of fully active human apelin receptor (APJR) complexed with heterotrimeric G protein in both 2:1 (dimer:G protein) and 1:1 (monomer:G protein) stoichiometric ratios were determined; structural differences in G protein engagement between dimeric and monomeric APJR suggest a role for stoichiometry in GPCR-G protein coupling and downstream signaling; a small hydrophobic dimer interface was identified.\",\n      \"method\": \"Cryo-EM single-particle analysis with ELA and synthetic small molecule ligands\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryo-EM structure with functional implications, two ligand conditions\",\n      \"pmids\": [\"35817871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A single residue mutation I109A (I109^3.32) in transmembrane domain 3 of APJ converts a balanced receptor into a G protein-biased receptor: it retains full ligand binding and G protein activation but is defective in GRK recruitment, β-arrestin recruitment, and downstream receptor-mediated ERK activation; molecular dynamics simulations indicated that the Phe-13 residue of apelin rotates to form new hydrophobic interactions with TM3 residues (F110, M113), stabilizing the biased conformation.\",\n      \"method\": \"Site-directed mutagenesis, G protein activation assay, GRK/β-arrestin recruitment assays, ERK phosphorylation, molecular dynamics simulation\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — active-site mutagenesis with functional assays and MD simulation, single lab\",\n      \"pmids\": [\"30409826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of APLNR-Gi1 complexes bound to three agonists with divergent signaling profiles identified 'twin hotspots' in APLNR as key determinants for G protein vs. β-arrestin signaling bias; structure-guided design produced G protein-biased agonists WN353 and WN561, which showed superior therapeutic effects against cardiac hypertrophy with reduced adverse effects compared to established APLNR agonists.\",\n      \"method\": \"Cryo-EM structure determination, functional signaling assays, structure-based rational drug design, in vivo cardiac hypertrophy pathophysiology experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple cryo-EM structures, structure-guided mutagenesis and ligand design, in vivo functional validation\",\n      \"pmids\": [\"38428423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"APLN is produced by Sertoli cells in response to high glucose, and hyper-activated APLN/APJ signaling in diabetic testes suppresses carnitine production and represses cell adhesion gene expression in Sertoli cells, causing blood-testis barrier (BTB) structural dysfunction and impaired spermatogenesis; pharmacological blockade of APLN/APJ with ML221 ameliorated BTB damage and improved spermatogenesis in diabetic db/db mice and cultured human testes.\",\n      \"method\": \"STRT-seq single-cell transcriptomics of human diabetic testes, in vitro Sertoli cell culture with high glucose, pharmacological inhibition with ML221, db/db diabetic mouse model, human testis culture\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — single-cell transcriptomics, in vitro mechanistic studies, in vivo mouse model, human tissue validation\",\n      \"pmids\": [\"36443325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Apelin induces cholangiocyte proliferation through Nox4/ROS/ERK-dependent signaling and activates hepatic stellate cells (HSCs) through intracellular ROS; APLN knockout or APJ antagonism (ML221) reduced bile duct ligation-induced cholangiocyte proliferation, liver inflammation, fibrosis, and angiogenesis in mice.\",\n      \"method\": \"Pharmacological inhibition (ML221, Nox4 inhibitor DPI, NAC, PD98059), APLN knockout mice, bile duct ligation model, Mdr2-/- mice, in vitro human biliary epithelial cells and HSC lines\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout and pharmacological inhibition, multiple inhibitors targeting specific pathway components, in vitro and in vivo models\",\n      \"pmids\": [\"32964473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Elabela/Toddler and apelin bind differently to the apelin receptor: alanine scanning of ELA showed the C-terminus carries the key pharmacophore; Asp282/Asp284 of rat/human apelin receptor are critical for apelin binding and activity but are NOT involved in Elabela/Toddler activity, demonstrating distinct binding modes for the two endogenous ligands.\",\n      \"method\": \"Alanine scanning mutagenesis of ELA, site-directed mutagenesis of apelin receptor, binding affinity assays, cAMP inhibition assay, β-arrestin 2 recruitment assay in CHO cells\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic alanine scanning and receptor mutagenesis with functional assays, single lab\",\n      \"pmids\": [\"32301550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Apelin-13, pGlu1-apelin-13, apelin-17, apelin-36, Elabela-21, and Elabela-32 exhibit distinct signaling profiles at APJ: all activate both G protein-dependent (cAMP inhibition, Ca2+ mobilization, early-phase ERK activation) and β-arrestin-dependent (GRKs, β-arrestin 1/2, AP2) pathways in a dose-dependent manner, but with different bias ratios; Elabela-32 showed >1000-fold bias to β-arrestin-dependent signaling, and apelin-17 was biased toward β-arrestin-dependent signaling.\",\n      \"method\": \"cAMP assay, Ca2+ mobilization, ERK phosphorylation, β-arrestin 1/2 recruitment assay, GRK assay, AP2 assay in APJ-expressing cells\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal signaling assays for multiple ligands, single lab\",\n      \"pmids\": [\"33746758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Protamine binds the apelin receptor (APJ) with 390 nM affinity and acts as a full antagonist of both G protein and β-arrestin-dependent intracellular signaling; ex vivo and in vivo, protamine abolishes apelin-mediated angiogenesis, glucose tolerance improvement, and vasodilatation; protamine's APJ antagonist activity is fully reversed by heparin both in vitro and in vivo.\",\n      \"method\": \"Cell-based fluorescence microscopy screening assay for APJ antagonism, radioligand binding, cAMP and β-arrestin signaling assays, ex vivo angiogenesis and vasodilatation assays, in vivo glucose tolerance and angiogenesis tests, heparin reversal experiments\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — binding affinity quantified, multiple signaling assays, in vitro, ex vivo, and in vivo validation, heparin reversal mechanism established\",\n      \"pmids\": [\"28242772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Apelin (APLN-13 and APLN-17) increases steroidogenesis (basal and IGF1-induced progesterone and estradiol) in human luteinized granulosa cells through activation of AKT and MAPK3/1 (ERK1/2) pathways and increased HSD3B protein expression; these effects are reversed by the APLNR antagonist ML221.\",\n      \"method\": \"RT-PCR, immunoblotting, pharmacological inhibitors of PI3K/Akt and MAPK, APJ antagonist ML221, steroid hormone ELISA\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibitors of specific pathways, receptor antagonist confirmation, single lab\",\n      \"pmids\": [\"27683264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In bovine granulosa cells, APLN-13 and APLN-17 increase progesterone production via MAPK ERK1/2 and increase cell proliferation via AKT signaling (blocked by ML221); conversely, APLN-13 and APLN-17 arrest bovine oocytes at germinal vesicle stage during in vitro maturation, associated with decreased progesterone, inhibited ERK1/2 phosphorylation, and increased PRKA phosphorylation.\",\n      \"method\": \"In vitro bovine granulosa cell culture, in vitro oocyte maturation, pharmacological inhibition, immunoblotting for ERK1/2 and AKT, ML221 antagonist\",\n      \"journal\": \"Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor antagonist and pathway inhibitor experiments, dual cell type mechanistic study, single lab\",\n      \"pmids\": [\"28250234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Apelin promotes lymphangiogenesis: APJ is expressed in lymphatic endothelial cells (LECs) and activates apelinergic signaling; apelin treatment enhances LEC migration, protects against UV-induced apoptosis, increases spheroid formation, stimulates in vitro tube formation, and promotes in vivo lymphatic microvessel invasion; apelin overexpression in tumor cells increases intratumoral lymphangiogenesis and lymph node metastasis.\",\n      \"method\": \"APJ expression in LECs by immunofluorescence, in vitro migration, apoptosis, 3D spheroid, tube formation assays, in vivo matrigel plug assay, apelin-overexpressing tumor xenograft model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro assays and in vivo model, single lab\",\n      \"pmids\": [\"24962866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Apelin deficiency in mice increases NADPH-stimulated superoxide levels in atria and slows atrial conduction velocities; apelin administration in mice with increased AF vulnerability reduced AF incidence/duration, prolonged atrial refractory periods, accelerated conduction velocity, and increased action potential duration; these electrophysiological effects were associated with increased atrial cardiomyocyte sodium currents.\",\n      \"method\": \"Apelin gene knockout mice, optical mapping of Langendorff-perfused isolated hearts, patch-clamp sodium current measurements, in vivo electrophysiology, NADPH oxidase activity assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with defined ionic and electrophysiological mechanism, multiple orthogonal methods\",\n      \"pmids\": [\"32879139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The exerkine apelin is induced by muscle contraction; apelin or APLNR deficiency in mice causes age-dependent muscle dysfunction; restoration of apelin signaling enhances muscle function by triggering mitochondriogenesis, autophagy, and anti-inflammatory pathways in myofibers, and enhances regenerative capacity by targeting muscle stem cells.\",\n      \"method\": \"Apelin and APLNR knockout mice, apelin replacement strategies, exercise models, muscle stem cell assays, mitochondrial function assays, autophagy markers\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function in two models (apelin-/- and APLNR-/-), restoration experiments, multiple mechanistic readouts\",\n      \"pmids\": [\"30061698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Apelin controls fetal glucose homeostasis: intravenous apelin injection in pregnant rats increases transplacental glucose transport; intraperitoneal apelin in neonates increases glucose uptake in lung and muscle; the apelinergic system is expressed at the fetoplacental interface and in multiple fetal tissues; placenta releases high amounts of apelin in late gestation ex vivo.\",\n      \"method\": \"Intravenous apelin administration in pregnant rats, radiolabeled glucose transplacental transport assay, intraperitoneal injection in neonates with tissue glucose uptake measurement, RT-PCR and immunostaining for tissue expression\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct in vivo apelin administration with functional metabolic readouts, single lab\",\n      \"pmids\": [\"26631739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"APJ is expressed at cellular junctions in human umbilical vein endothelial cells (HUVECs) and may associate with PECAM-1; siRNA-mediated silencing of APJ influences shear-induced cytoskeletal remodeling, cellular elasticity, motility, attachment, and distribution of adhesion complexes in endothelial cells.\",\n      \"method\": \"siRNA knockdown of APJ, immunofluorescence localization, atomic force microscopy for cellular elasticity, motility and adhesion assays in HUVECs under shear flow\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple functional readouts under physiological flow conditions, single lab\",\n      \"pmids\": [\"29369349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Apelin improves endothelial cell dysfunction in diabetes by decreasing apoptosis, reducing adhesion molecule expression, and increasing proliferation, angiogenesis, and expression of E-cadherin, VEGFR2, and Tie-2; these effects were dependent on APJ and downstream NF-κB pathways, as confirmed by endothelial cell-specific APJ knockout mice.\",\n      \"method\": \"Endothelial cell-specific APJ knockout mice, cultured endothelial cell assays, NF-κB pathway analysis, in vivo diabetic cardiomyopathy model\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional knockout with pathway analysis, single lab\",\n      \"pmids\": [\"33504680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Apelin is identified as a factor secreted by brain endothelial cells (by mass spectrometry proteomics) that maintains glioblastoma stem-like cell expansion; genetic and pharmacological targeting of the apelin receptor abrogates apelin- and endothelial-mediated expansion of glioblastoma stem-like cells in vitro and suppresses tumor growth in vivo.\",\n      \"method\": \"Mass spectrometry proteomic characterization of brain endothelial cell secretome, genetic apelin receptor targeting, competitive APJ antagonists, in vivo xenograft GBM model\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS identification plus genetic and pharmacological validation in vitro and in vivo, single lab\",\n      \"pmids\": [\"29053791\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Apelin (APLN) is a peptide hormone processed from a 77-amino acid precursor that acts as an endogenous ligand for the G protein-coupled receptor APJ (APLNR), signaling through Gαi2/i3 (via rearrangement), Gαo, and Gαq to activate PI3K/Akt, MAPK/ERK, and AMPK pathways; it is transcriptionally induced by hypoxia via HIF-1α binding to an intronic HRE, by β-catenin in hepatocellular carcinoma, and by muscle contraction; apelin peptides are rapidly inactivated by ACE2 and neutral endopeptidase (NEP); crystal and cryo-EM structures of APJR revealed a two-site peptide binding mode and G protein stoichiometry-dependent signaling, with a key I109^3.32 residue controlling β-arrestin bias; apelin mediates cardiovascular protection (positive inotropy, NO-dependent vasodilatation, cardioprotection via RISK pathway/MPTP delay), promotes angiogenesis and lymphangiogenesis, controls cardiac precursor migration during gastrulation, enhances muscle mitochondriogenesis and autophagy, regulates cholangiocyte proliferation via Nox4/ROS/ERK, and modulates spermatogenesis by controlling Sertoli cell carnitine production and BTB integrity through the APLN/APJ axis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Apelin (APLN) is a secreted peptide hormone, processed from a precursor into multiple bioactive forms (apelin-13, apelin-17, apelin-36), that acts as an endogenous agonist of the G-protein-coupled apelin receptor APJ/APLNR to coordinate cardiovascular, angiogenic, metabolic, and tissue-protective programs [#0]. Engagement of APJ activates Gαi2/Gαi3 by molecular rearrangement and Gαo/Gαq by classical dissociation [#9], driving PI3K/Akt and MAPK/ERK signaling that underlies its cellular effects, including cardioprotection against ischemia-reperfusion injury via the RISK pathway and delay of mitochondrial permeability transition pore opening [#2]. Receptor activation is followed by GRK2-mediated, β-arrestin1-independent, clathrin/dynamin-dependent internalization, and downstream signaling bias is encoded structurally: the I109^3.32 residue of TM3 controls the balance between G protein and β-arrestin/GRK recruitment [#15, #8], and structure-guided design of G-protein-biased agonists yields improved efficacy against cardiac hypertrophy [#16]. Crystal and cryo-EM structures defined a curved two-site peptide binding mode and stoichiometry-dependent G protein coupling, and showed that the second endogenous ligand Elabela/Toddler engages APJ through a distinct binding mode from apelin [#7, #14, #19]. APLN is transcriptionally induced by hypoxia through HIF-1α binding to an intronic hypoxia-responsive element [#1], by β-catenin in hepatocellular carcinoma [#12], and by muscle contraction as an exerkine [#26]. Functionally, apelin marks and drives sprouting (tip) endothelial cells in angiogenesis [#5], promotes lymphangiogenesis [#24], directs cardiac precursor migration during gastrulation [#3], enhances muscle mitochondriogenesis and autophagy [#26], and protects vasculature against aneurysm and oxidative injury [#13, #25]; its peptides are inactivated by ACE2 and by neutral endopeptidase [#0, #13]. The APLN/APJ axis also regulates Sertoli-cell carnitine production and blood-testis barrier integrity [#17] and cholangiocyte proliferation through Nox4/ROS/ERK signaling [#18], and apelin inhibition reduces tumor angiogenesis and glioblastoma stem-like cell expansion [#11, #30].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that apelin peptides arise from a single gene to activate the GPCR APJ and are inactivated by ACE2, defining the core ligand-receptor-degradation axis.\",\n      \"evidence\": \"Biochemical/pharmacological characterization and review of experimental literature\",\n      \"pmids\": [\"15907343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the G protein coupling specificity downstream of APJ\", \"Tissue-specific roles of distinct peptide isoforms unaddressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined a developmental requirement for apelin/APJ signaling in directing convergence of cardiac precursors, showing the axis is not merely a metabolic/cardiovascular modulator but a morphogenetic cue.\",\n      \"evidence\": \"Zebrafish loss- and gain-of-function genetics with in situ hybridization and confocal imaging of precursor migration\",\n      \"pmids\": [\"17336905\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mammalian conservation of this gastrulation role not established here\", \"Downstream effectors driving directional migration unidentified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified the signaling pathways for apelin cardioprotection, showing PI3K-Akt and ERK (RISK pathway) activation and MPTP delay mediate protection against ischemia-reperfusion.\",\n      \"evidence\": \"In vivo rodent I/R, Langendorff perfusion, isolated cardiomyocytes, PI3K and MEK inhibitors\",\n      \"pmids\": [\"17694254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-proximal coupling to PI3K/ERK not dissected\", \"Did not address chronic versus acute cardiac effects\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved how apelin transcription is regulated under stress, demonstrating HIF-1α directly binds an intronic HRE to induce apelin during hypoxia and that this drives endothelial proliferation and vessel regeneration.\",\n      \"evidence\": \"ChIP, reporter assays with mutagenesis, siRNA knockdown, zebrafish fin regeneration\",\n      \"pmids\": [\"18617693\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other transcriptional inputs not yet mapped\", \"Quantitative contribution of apelin to in vivo angiogenesis not isolated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Clarified the heterotrimeric G protein logic of APJ, showing Gαi2/Gαi3 activate by molecular rearrangement while Gαo/Gαq dissociate classically, refining how a single receptor produces diverse outputs.\",\n      \"evidence\": \"BRET/FRET in live HEK293 cells with fluorescent G-protein subunits\",\n      \"pmids\": [\"25193074\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab live-cell assay without structural confirmation\", \"Functional consequences of rearrangement versus dissociation untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated apelin specifically marks and is functionally required in sprouting (tip) endothelial cells, downstream of VEGF-VEGFR2, distinguishing active from quiescent vasculature.\",\n      \"evidence\": \"Apln-CreER lineage tracing, tumor and ischemia models, genetic ablation\",\n      \"pmids\": [\"25597280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking VEGFR2 to apelin transcription unresolved\", \"Autocrine versus paracrine action on tip cells not distinguished\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified Elabela/Toddler as a second endogenous APJ agonist that drives internalization, cAMP suppression, ERK activation, and angiogenesis, expanding the receptor's ligand repertoire.\",\n      \"evidence\": \"Reconstituted HEK293/CHO systems, cAMP, ERK, calcium assays, aortic ring relaxation\",\n      \"pmids\": [\"25639753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative physiological roles of apelin versus Elabela unclear\", \"Tissue contexts of preferential ligand use undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended apelin/APJ signaling into adipose thermogenesis and metabolism, showing PI3K/Akt and AMPK drive browning, mitochondrial biogenesis, and oxygen consumption.\",\n      \"evidence\": \"Adipocyte differentiation assays, pathway inhibitors, mouse model, mitochondrial function assays\",\n      \"pmids\": [\"25931124\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding\", \"In vivo contribution to whole-body energy balance not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided the first atomic-resolution view of APJ, revealing a curved two-site ligand binding mode and the residues governing apelin recognition.\",\n      \"evidence\": \"X-ray crystallography at 2.6 Å with a peptide mimetic, mutagenesis, MD simulation\",\n      \"pmids\": [\"28528775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Captured with a mimetic rather than native peptide\", \"G-protein-bound active state not resolved in this structure\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified protamine as a full APJ antagonist whose activity is reversed by heparin, providing a pharmacological tool blocking both G protein and β-arrestin signaling and abolishing apelin-mediated angiogenesis and vasodilatation.\",\n      \"evidence\": \"Binding, cAMP and β-arrestin assays, ex vivo and in vivo functional tests, heparin reversal\",\n      \"pmids\": [\"28242772\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specificity of protamine for APJ versus other targets not fully bounded\", \"Therapeutic window not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Dissected APJ trafficking, showing apelin-induced internalization is GRK2- and dynamin/EPS15-dependent but β-arrestin1-independent, and that ERK desensitization occurs upstream of internalization.\",\n      \"evidence\": \"Dominant-negative constructs and fluorescence imaging of APJ internalization in HEK293\",\n      \"pmids\": [\"27492965\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-lab dominant-negative approach\", \"Role of β-arrestin2 versus β-arrestin1 not separated\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped signaling bias to a single TM3 residue, showing I109A converts APJ into a G-protein-biased receptor defective in GRK and β-arrestin recruitment, establishing a structural basis for biased agonism.\",\n      \"evidence\": \"Site-directed mutagenesis, G protein/arrestin recruitment assays, ERK assay, MD simulation\",\n      \"pmids\": [\"30409826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-lab mutagenesis\", \"In vivo consequences of forced bias not tested in this study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined apelin as a contraction-induced exerkine essential for muscle homeostasis, with loss causing age-dependent dysfunction and restoration enhancing mitochondriogenesis, autophagy, and stem-cell-mediated regeneration.\",\n      \"evidence\": \"Apelin and APLNR knockout mice, replacement and exercise models, muscle stem cell and mitochondrial assays\",\n      \"pmids\": [\"30061698\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular targets in myofibers versus stem cells not fully separated\", \"Human translatability of the aging phenotype untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked apelin to electrophysiological stability, showing apelin deficiency raises atrial superoxide and slows conduction while apelin reduces atrial fibrillation vulnerability via increased sodium currents.\",\n      \"evidence\": \"Apelin knockout mice, optical mapping, patch-clamp sodium currents, NADPH oxidase assay\",\n      \"pmids\": [\"32879139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-to-sodium-channel coupling mechanism unresolved\", \"Relevance to human atrial fibrillation not directly tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established apelin as a vasoprotective factor in aneurysm, identifying NEP as a degrading enzyme, showing apelin induces ACE2, and validating a NEP-resistant analog therapeutically.\",\n      \"evidence\": \"Apln knockout mice, Ang II-induced AAA, aortic SMC culture, peptide analog design, Ldlr-/- model\",\n      \"pmids\": [\"31189595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Balance between ACE2 induction (protective) and ACE2 degradation of apelin not fully reconciled\", \"Long-term analog safety not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed APLN is a β-catenin transcriptional target in hepatocellular carcinoma that promotes tumor proliferation through PI3K/Akt-GSK3β-cyclin D1 signaling, connecting Wnt pathway activation to apelin-driven oncogenesis.\",\n      \"evidence\": \"β-catenin ChIP at APLN promoter, ectopic expression/knockdown, Western blot, xenograft\",\n      \"pmids\": [\"31410213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study\", \"Autocrine versus paracrine APJ engagement in tumor not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Captured fully active APJR-G protein complexes in both 2:1 and 1:1 stoichiometries, implicating receptor dimerization stoichiometry in shaping G protein coupling.\",\n      \"evidence\": \"Cryo-EM single-particle analysis with ELA and small-molecule ligands\",\n      \"pmids\": [\"35817871\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological prevalence of dimeric versus monomeric signaling in cells unknown\", \"Functional output differences between stoichiometries not directly measured\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified structural 'twin hotspots' governing G protein versus β-arrestin bias and used them to design G-protein-biased agonists with superior anti-hypertrophic efficacy, translating structural insight into improved therapeutics.\",\n      \"evidence\": \"Multiple cryo-EM structures, signaling assays, structure-based design, in vivo cardiac hypertrophy models\",\n      \"pmids\": [\"38428423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term in vivo safety of biased agonists not established\", \"Generalizability of hotspots to other peptide GPCRs untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated distinct binding determinants for the two endogenous ligands, showing Asp282/Asp284 are critical for apelin but not Elabela, mechanistically separating their receptor engagement.\",\n      \"evidence\": \"Alanine scanning of ELA, receptor mutagenesis, binding, cAMP, β-arrestin2 assays in CHO cells\",\n      \"pmids\": [\"32301550\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-lab study\", \"Structural basis of differential engagement not visualized here\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Catalogued ligand-specific bias across apelin and Elabela isoforms, showing all engage both G protein and β-arrestin pathways but with markedly different bias ratios.\",\n      \"evidence\": \"cAMP, Ca2+, ERK, β-arrestin1/2, GRK, AP2 assays in APJ cells\",\n      \"pmids\": [\"33746758\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab quantitative bias values\", \"Physiological relevance of extreme bias ratios untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed a pathological APLN/APJ role in diabetic testis, where Sertoli-cell apelin suppresses carnitine production and adhesion genes to disrupt the blood-testis barrier, reversible by antagonist ML221.\",\n      \"evidence\": \"Single-cell transcriptomics of human diabetic testes, Sertoli cell culture, db/db mice, human testis culture, ML221\",\n      \"pmids\": [\"36443325\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional link between APJ signaling and adhesion gene repression not fully mapped\", \"Reversibility window in human disease unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined apelin's profibrotic role in liver, driving cholangiocyte proliferation through Nox4/ROS/ERK and activating hepatic stellate cells via ROS, with knockout or antagonism reducing fibrosis.\",\n      \"evidence\": \"APLN knockout mice, bile duct ligation, Mdr2-/- mice, pathway inhibitors, biliary and HSC cultures\",\n      \"pmids\": [\"32964473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Source of apelin within injured liver not fully resolved\", \"Crosstalk with other fibrogenic signals undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How tissue context selects among apelin's many divergent outputs—protective versus profibrotic versus pro-tumorigenic—and how ligand identity, receptor bias, and stoichiometry are integrated in vivo remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking biased agonism to specific physiological versus pathological outcomes\", \"Endogenous peptide isoform balance in different tissues uncharacterized\", \"Predictive rules for therapeutic agonist versus antagonist choice not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 6, 7, 20]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [9, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 26, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 9]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 5, 24]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [1, 26]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 12, 13, 17, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"APLNR\", \"ACE2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}